An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab

An Observational, Prospective, Multicenter, Local, to Assess the Quality of Life Through the Use of Questionnaires in a Cohort of Patients With Rheumatoid Arthritis Treated With Anti-CD20 Therapy

This multicenter prospective observational study will evaluate the quality of life in participants with rheumatoid arthritis (RA) who are initiated with rituximab (MabThera/Rituxan). Participants will be followed for 6 months from initiation of treatment.

Inclusion Criteria:

• Adult participants of both genders who are 18 years or older
• Diagnosis of RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) of 1987 for the RA classification
• Participants with medically prescribed or being administered with unique rituximab infusion in the least 3 days, according to the approved label
• Ability to meet the program's requirements and to voluntarily sign the Informed Consent Term.

Exclusion Criteria:

• Participants who have received any investigational medication within less than or equal to (<=) 1 year before the first dose of the currently indicated treatment
• Participants with an active infection
• Participants with conditions that may interfere in the ability to understand the requests of data collection and to obey to the study's requirements
• Functional Class IV defined based on the ACR functionality criteria for RA
• Participants who can not or who do not want, for any reason, to answer the questionnaires.